Service-Tutorial-Lab near Tache MB (638 Result(s))

Saving Lives Through Early Disease DiagnosisMiraculins is an emerging biotechnology company committed to extending life, reducing suffering and lowering healthcare costs. Through our leadership in the development and commercialization of diagnostic tests, we strive to improve the overall diagnosis and treatment of patients by enhancing the information available to physicians.The Miraculins AdvantageProducts & ProgramsMiraculins is dedicated to the development and commercialization of diagnostic tests and risk assessment technologies for diseases and conditions that are lacking highly sensitive and specific tests.

Our ProductsAGGRASTAT® - US GP IIb/IIIa inhibitor market - $400 million (AGGRASTAT® + two competitors)TARDOXALTM - in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet needAbout MedicureMedicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics.HistoryMedicure founded in 1997 is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. Medicure has raised over $140 million and focused this investment on the advancement and clinical development of cardiovascular drugs. In 2006 Medicure acquired the USA commercial rights to AGGRASTAT (tirofiban HCl), a cardiovascular drug originally developed by Merck. AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome. Medicurés business is generating revenue to support operations and to make selected investments in the clinical advancement of AGGRASTAT.TodayMedicurés core focus is on the US commercial sales of its FDA approved small molecule, AGGRASTAT.

Global M2M Connectivity Solutions - Better Coverage, Choice & ReliabilityKORE is the world's leading provider of machine-to-machine (M2M) network services - offering truly global connectivity over GSM, CDMA & Satellite technologies. We deliver network services to application solution providers and enterprises supported by a wireless operator grade, distributed and highly scalable business management platform that presents all network services and technologies through a single, unified interface.

7% of Canadians have Macular DegenerationBy 2030, over 20% of Canadians will have Macular Degeneration1 in 9 of those over 65 have reduced visionResearch studies tell us that individuals who are legally blind would give up 60% of their remaining lifespan to see again1 in 4 of those over 80 have a vision impairmentEye Canada 2009 Helping You See BetterFocusing on Low Vision Care in Canada 2-1200 Waverley Street, Winnipeg, Manitob,a Canada